Close Menu


Pfizer is the first drugmaker to join the Strata PATH platform trial and will contribute drugs to advanced cancer patients in four study arms.

Celcuity will use its CELsignia Multi-Pathway Activity Test to identify patients with hyperactive HER2 and c-MET signaling pathways.

The test will be used in the trial to improve understanding of molecular resistance mechanisms to Pfizer's Lorviqua and other ALK inhibitors.

The agency approved the drug based on a study that showed an 88 percent response rate in young patients with ALK-positive anaplastic large cell lymphoma.

Verzenio, Ibrance, Rubraca, and bintrafusp alfa are some of the precision oncology products companies provided updates on during the conference.  

The company is evaluating its investigational PKC inhibitor with Pfizer's cMET inhibitor as a treatment for metastatic uveal melanoma patients.

Although the pandemic may have been at the forefront of readers' minds, they remained interested in the latest advances and controversies in precision oncology.

The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.

In the study, more than 80 percent of multiple myeloma patients with BRAF V600E mutations saw their tumor shrink after receiving Braftovi and Mektovi.

The studies will evaluate Lorbrena in patients with newly diagnosed, high-risk neuroblastoma whose tumors harbor an ALK gene mutation.